Biomarkers of Early Sepsis May Be Correlated with Outcome

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2014 Jun 3

PMID 24886652

Citations 14

Authors

Tsai-Hsia Hong

Chin-Hao Chang

Wen-Je Ko

Ching-Feng Lin

Heng-Hsiu Liu

Lu-Ping Chow

Chun-Ta Huang

Sun-Liang Yu

Yih-Sharng Chen

Affiliations

Soon will be listed here.

Abstract

Background: Sepsis causes high mortality, and the mortality due to secondary infections is even higher. No studies to date have investigated the time from the primary infection to death due to a secondary infection; similarly, the factors that are significantly different in sepsis survivors relative to non-survivors or in severe sepsis patients who suffered a late death relative to those who recover have not been explored. We hypothesized that patients who survive sepsis have a weaker pro-inflammatory response than those who do not and that the mid-term survivors (which acquire secondary infections) would have a pronounced anti-inflammatory response (making them susceptible to infection); this hypothesis was verified in this study.

Methods: We examined 24 patients with severe sepsis; the patients were subdivided by outcome into early death (n=5), mid-term survival (survival through severe sepsis but death within six months or continued hospitalization for six months, n=6), and long-term survival (recovery and survival for more than six months, n=13) groups. The levels of CD3+, CD4+, CD8+, and CD19+ lymphocytes were analyzed by flow cytometry, and the plasma levels of carbonic anhydrase IX (CA IX), MCP-1, IL-6, IL-7, IL-8, and IL-10 were measured by ELISA on days 0, 1, 2, and 3. A statistical comparison of the variables in the groups was conducted using a mixed model.

Results: The plasma levels of MCP-1, IL-6, and IL-8 in early death and survivors were significantly different, and all had p values<0.01. The plasma levels of MCP-1, IL-6, and IL-8 were also significantly different in mid-term survivors and long-term survivors, with p values of <0.01, 0.04, and <0.01, respectively.

Conclusions: Our data support the hypothesis that survivors have a weaker pro-inflammatory response than non-survivors, but the mid-term survivors did not have a more pronounced anti-inflammatory response. The levels of pro-inflammatory cytokines in the mid-term and long-term survivors were significantly different.

Citing Articles

Plasma neutrophil extracellular traps in patients with sepsis-induced acute kidney injury serve as a new biomarker to predict 28-day survival outcomes of disease.

He J, Zheng F, Qiu L, Wang Y, Zhang J, Ye H Front Med (Lausanne). 2024; 11:1496966.

PMID: 39629231 PMC: 11611547. DOI: 10.3389/fmed.2024.1496966.

Using time-course as an essential factor to accurately predict sepsis-associated mortality among patients with suspected sepsis.

Yen S, Wu C, Tseng Y, Li C, Chen K Biomed J. 2023; 47(3):100632.

PMID: 37467969 PMC: 11332986. DOI: 10.1016/j.bj.2023.100632.

Evaluation of Biomarkers from Peritoneal Fluid as Predictors of Severity for Abdominal Sepsis Patients Following Emergency Laparotomy.

Zhao J, Zhang T, Deng Z, Han X, Ma T, Xie K J Inflamm Res. 2023; 16:809-826.

PMID: 36876154 PMC: 9974770. DOI: 10.2147/JIR.S401428.

Oncostatin M Receptor Type II Knockout Mitigates Inflammation and Improves Survival from Sepsis in Mice.

Salim S, AlMalki N, Macala K, Wiedemeyer A, Mueller T, Churchill T Biomedicines. 2023; 11(2).

PMID: 36831019 PMC: 9953488. DOI: 10.3390/biomedicines11020483.

Dexpanthenol attenuates inflammatory damage and apoptosis in kidney and liver tissues of septic mice.

Zhao X, Zhang S, Shao H Bioengineered. 2022; 13(5):11625-11635.

PMID: 35510377 PMC: 9275904. DOI: 10.1080/21655979.2022.2070585.

References

Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z . Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006; 212:8-27. DOI: 10.1111/j.0105-2896.2006.00427.x. View

Ward N, Casserly B, Ayala A . The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008; 29(4):617-25, viii. PMC: 2786900. DOI: 10.1016/j.ccm.2008.06.010. View

Vincent J, Sakr Y, Sprung C, Ranieri V, Reinhart K, Gerlach H . Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006; 34(2):344-53. DOI: 10.1097/01.ccm.0000194725.48928.3a. View

Chen X, Ye J, Ye J . Analysis of peripheral blood lymphocyte subsets and prognosis in patients with septic shock. Microbiol Immunol. 2011; 55(10):736-42. DOI: 10.1111/j.1348-0421.2011.00373.x. View

Aziz M, Jacob A, Yang W, Matsuda A, Wang P . Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol. 2012; 93(3):329-42. PMC: 3579020. DOI: 10.1189/jlb.0912437. View

Eckert A, Kappler M, Schubert J, Taubert H . Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients. Oral Maxillofac Surg. 2012; 16(2):189-96. DOI: 10.1007/s10006-012-0335-8. View

Hotchkiss R, Swanson P, Cobb J, Jacobson A, Buchman T, KARL I . Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care Med. 1997; 25(8):1298-307. DOI: 10.1097/00003246-199708000-00015. View

Suffredini A, Munford R . Novel therapies for septic shock over the past 4 decades. JAMA. 2011; 306(2):194-9. DOI: 10.1001/jama.2011.909. View

Angus D, Lidicker J, Clermont G, Carcillo J, Pinsky M . Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29(7):1303-10. DOI: 10.1097/00003246-200107000-00002. View

10.

Blumenstein M, Boekstegers P, Fraunberger P, Andreesen R, Fingerle-Rowson G . Cytokine production precedes the expansion of CD14+CD16+ monocytes in human sepsis: a case report of a patient with self-induced septicemia. Shock. 1997; 8(1):73-5. DOI: 10.1097/00024382-199707000-00012. View

11.

Hotchkiss R, Karl I . The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348(2):138-50. DOI: 10.1056/NEJMra021333. View

12.

Bozza F, Salluh J, Japiassu A, Soares M, Assis E, Gomes R . Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007; 11(2):R49. PMC: 2206478. DOI: 10.1186/cc5783. View

13.

Shubin N, Monaghan S, Ayala A . Anti-inflammatory mechanisms of sepsis. Contrib Microbiol. 2011; 17:108-124. DOI: 10.1159/000324024. View

14.

Martin G, Mannino D, Eaton S, Moss M . The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348(16):1546-54. DOI: 10.1056/NEJMoa022139. View

15.

Angus D . The search for effective therapy for sepsis: back to the drawing board?. JAMA. 2011; 306(23):2614-5. DOI: 10.1001/jama.2011.1853. View

16.

Hoser G, Skirecki T, Zlotorowicz M, Zielinska-Borkowska U, Kawiak J . Absolute counts of peripheral blood leukocyte subpopulations in intraabdominal sepsis and pneumonia-derived sepsis: a pilot study. Folia Histochem Cytobiol. 2012; 50(3):420-6. DOI: 10.5603/19751. View